Promising results from malaria-prevention medication among children in Borno State, Nigeria

Content provided by APO Group. CNBC Africa provides content from APO Group as a service to its readers, but does not edit the articles it publishes. CNBC Africa is not responsible for the content provided by APO Group.
Download logo

“I had always asked my family members to sit outside for one or two hours at night just before bedtime, when I usually spray the bedroom with indoor sprays,” says Hajia Hauwa Abiso, who lives in the north-eastern Nigerian state of Borno. “Little did I know that mosquito bites during this period were enough to infect them.”

When she learned about the danger of mosquito bites at night, she worried that her 3-year-old child might be infected with malaria. “Since my child received the antimalaria drugs given during the campaign, and I started to use lessons from the radio drama on household practices for malaria prevention, my children have hardly fallen ill of malaria,” she explains, with great relief.

Hajia Hauwa is the mother of one of the 1.2 million children younger than 5 years reached in four cycles of house-to-house campaigns since 2017 by the World Health Organization (WHO) and partners in Borno State with the seasonal malaria chemoprevention.

WHO recommends the intermittent administration of full treatment courses of an oral antimalarial medicine to children in areas with high transmission rates during the malaria season.

Even though malaria control in Borno State remains a public health challenge, there are suboptimal availability and use of prevention and treatment interventions, such as insecticide-treated bed nets and accessibility to health facilities for diagnosis and treatment using quality-assured artemisinin-based combination drug therapy.

WHO estimates that more than half of the recorded deaths in Borno State in 2018 were due to malaria combined with malnutrition – more than all other causes of death combined, including cholera, measles and hepatitis E.

Seasonal malaria chemoprevention targets the protection of young children from malaria infection. A recent impact survey by WHO showed promising results on malaria morbidity and mortality in the state. Based on the incidence of malaria in children aged 3–59 months in 20 randomly selected clusters (using National Immunization Programme sample in 16 local government areas of Borno, the findings indicated fewer cases of malaria among children who participated in the seasonal malaria chemoprevention campaign, compared with children who did not receive the treatment.

The survey findings also showed that children living in areas where the campaign did not take place are at higher risk of malaria infection (at 16%), compared with children who received the treatment (at 5%).

“WHO is impressed by the results of the survey. It confirms our recommendation, and we urge health authorities to conduct seasonal malaria chemoprevention campaigns as a cost-effective and safe means to prevent malaria across the Sahel sub-region of Africa,” emphasizes Dr Matshidiso Moeti, WHO Regional Director for Africa.

With assistance from WHO, the Borno State Ministry of Health developed a strategy for malaria control in north-eastern Nigeria, with the seasonal malaria chemoprevention treatment as a critical tool for rapidly reducing malaria death and disease among young children.

“In emergencies such as in north-eastern Nigeria, the most effective ways to reduce morbidity and mortality due to malaria among children living in vulnerable conditions is through preventive measures, such as use of insecticide-treated nets, seasonal malaria chemoprevention and the provision of real-time lifesaving messages for prevention,” stresses Dr Clement Peter Lasuba, Officer in Charge for WHO Nigeria.

Borno State Malaria Programme Manager, Mala Waziri, agrees: “From the impact assessment of the seasonal malaria chemoprevention exercise in Borno State, it is evident that the intervention has helped to reduce the incidence of malaria in households, as less cases are reported in the clinics than previously.”

Distributed by APO Group on behalf of World Health Organization (WHO).

Related Content

Health care group RH Bophelo lists on the Rwanda Stock Exchange

South African multi-million health care company, RH Bophelo today cross-listed on the Rwanda Stock Exchange, making it the 9th company to be listed on the RSE stock market. This comes at a time when another South African company, Cimerwa PPC is also planning the same move. Celestin Rwabukumba, CEO, Rwanda Stock Exchange joins CNBC Africa for more.

The role of financial players in Rwanda’s post COVID-19 recovery

Financial institutions are expected to be central in the bounce-back of small and medium enterprises post-COVID-19. But how much of a role will it be? CNBC Africa's Arnold Kwizera spoke to Jane Mwangi, Managing Director, KCB Foundation for more.

Grading Buhari’s economic performance over the past 5 years

May 29th marked five years since President Muhammadu Buhari took over leadership in Nigeria. One year into his second tenure as president, Vincent Nwani, a Business and Investment Consultant joins CNBC Africa for an economic scorecard of Buhari’s lead administration.

Arunma Oteh on Adesina’s probe & why COVID-19 represents an opportunity for Africa

Some former African presidents have shown their support for the president of the African Development Bank, Akinwunmi Adesina. This was in a letter over the 16 count allegations levelled against him to which Adesina had stated his innocence. Although the ethics committee of the board of directors of the continental bank has cleared Adesina of these charges, the United States which is one of the major shareholders of the bank has called for an independent probe into the allegations.

Subscribe to our newsletter

Sign up for free newsletters and get more CNBC AFRICA delivered to your inbox

More from CNBC Africa

COVID-19 lock-down: This is how much SA’s alcohol ban cost the economy

After a two month ban on liquor sales, stores reopened today and thirsty consumers were waiting in line to replenish their stock. While the industry expects liquor sales to spike in the coming days, the ban on sales during the Covid-19 lock-downs has cost over 117,000 jobs. That’s according to the South African Liquor Brand owners Association (SALBA). SALBA CEO, Kurt Moore joins CNBC Africa for more.

Absa May manufacturing index surprises

The rand is rallying. Eight million people are back at work. Petrol will cost one rand and eighteen cents per litre more from next month and the latest Absa Purchasing Managers Index business activity sub-index rebounded to 43.2 in May after collapsing to an all-time low of 5.1 in April. The magnitude of the increase is surprising, given that most parts of the manufacturing sector could only operate at 30 per cent of employment capacity in May due to lockdown. Miyelani Maluleke, Economist at Absa Corporate and Investment Banking joins CNBC Africa for more.

COVID-19: Are Rwanda’s taxi motorbikes equipped for return?

Last night the Rwandan Prime Minister's office announced that the previously slated date of reopening of passenger motorbikes - which was meant to be today - has been extended until further notice. As the country gears up to reallow taxi-motorbikes to start operating again after over 2 months of being out of service due to Covid-19 measures; tech and mobility company, Pascal Technology has been hard at work equipping them to meet new regulatory measures. CNBC Africa spoke to Pascal Ndizeye, CEO and Founder, Pascal Technology to gauge their progress.

Health care group RH Bophelo lists on the Rwanda Stock Exchange

South African multi-million health care company, RH Bophelo today cross-listed on the Rwanda Stock Exchange, making it the 9th company to be listed on the RSE stock market. This comes at a time when another South African company, Cimerwa PPC is also planning the same move. Celestin Rwabukumba, CEO, Rwanda Stock Exchange joins CNBC Africa for more.

Partner Content

Sanlam Emerging Markets and its partners on the African continent invest over $12 million to fight COVID-19

As we go through this global pandemic together, it is the little things we miss. A high five, a handshake, a walk...

VIVO CEO is a dynamic leader for this innovative global brand

May 2020 -- Six months ago the vision for vivo in South Africa was just beginning to...

Trending Now

“Stop this culture of frivolous allegations” former World Bank Treasurer Arunma Oteh defends African Development Bank President

"So my appeal really is that we dispense of this issue. That we stop this culture of frivolous allegations around the times of elections. And allow the African Development Bank to support the African continent at this important time.”

How LGBTQ+ Pride Went From Movement To Marketing

With all of the changes to this year’s Pride lineup, many are left wondering how these virtual events will maintain their support of small LGBTQ+ owned businesses, like restaurants, bars, and brick-and-mortar stores, as well as LGBTQ+ focused nonpr

CNBC Africa celebrates 13 years on air

Today, June 1st marks our 13th Anniversary at CNBC Africa. As we celebrate our work and experiences at a time when the world is subdued by the coronavirus, here are views of some of our top analysts and friends from over the years....

Capital Appreciation’s Bradley Sacks on COVID-19 impact on business

Capital Appreciation, a JSE fintech player raised its final dividend by over 17 per cent following an increase in annual revenue and profits. The payment solutions provider saw increased demand for its digital and cloud based services and said the Covid-19 pandemic has not impacted earnings negatively. Bradley Sacks, Joint CEO at Capital Appreciation joins CNBC Africa for more.
- Advertisement -